Novo Nordisk A/S reported a 31% increase in sales to DKK 232.3 billion for 2023, with a significant 51% rise in net profit to DKK 83.7 billion; the company proposes a DKK 9.40 total dividend per share for 2023, enhancing returns for shareholders.